HOME >> BIOLOGY >> NEWS
Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic

Scientists report that an unlikely molecule has emerged as an attractive target for development of therapeutics aimed at a diverse spectrum of tumors, including some malignancies that are resistant to conventional therapies. Two studies published online in Cancer Cell demonstrate that the insulin-like growth factor 1 receptor (IGF-1R) is required for the survival of tumor cells and provide direct evidence that inhibition of IGF-R1 using selective small molecules represents a novel potential anticancer treatment.

Extensive studies have suggested that IGF-1R plays a role in the development of human cancers. IGF-1R is present in a broad range of tumor types including multiple myeloma, lymphoma, leukemia, and breast, lung, prostate, and colon cancers. However, IGF-1R has not been viewed as a likely target for cancer therapeutics because many normal cells also contain the protein. Research scientists from Dana-Farber Cancer Institute in Boston and Novartis Institutes for Biomedical Research Basel demonstrate that IGF-1R inhibition using a variety of methods had potent antitumor effects against many types of cancer cells grown in the laboratory, including cells that are resistant to conventional cancer therapeutics.

Molecular analyses demonstrated that IGF-1R inhibition impacts multiple intracellular signals related to cell proliferation or tumor development and provides possible mechanisms to explain how IGF-1R inhibition can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Perhaps most significantly, IGF-1R suppresses tumor growth, prolongs survival, and enhances the antitumor effect of chemotherapy in clinically relevant mouse models of multiple myeloma and other hematological malignancies. The researchers also identify two small molecules that are selective inhibitors of IGF-1R and are active anticancer agents against tumors that contain IGF-1R. These small molecules represent highly attractive potential therapeu
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
26-Feb-2004


Page: 1 2

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
3. Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
6. New Arizona State center brings science to policy on issues of water resources and urban growth
7. Researchers identify protein promoting vascular tumor growth
8. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
9. Growth hormone and IBD: Reduction of intestinal inflammation, promotion of growth
10. Extreme stretch-growth of axons
11. Diabodies act as guided missiles targeted to mammary tumor growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/20/2018)... Ontario (PRWEB) , ... November 20, 2018 , ... The ... system to track all newborn screening (NBS) specimens across the state. The ... from hospitals and delivery to the state newborn screening laboratory in Salt Lake City. ...
(Date:11/16/2018)... , ... November 16, 2018 , ... ... P.G., was awarded the International Bottled Water Association’s (IBWA’s) IBWA/Shayron Barnes-Selby Advocacy Award ... IBWA’s Advocacy Award, named “The Selby” after longtime IBWA contributor Shayron Barnes-Selby, is ...
(Date:11/15/2018)... TORONTO (PRWEB) , ... November 15, 2018 , ... Firmex ... Divestopedia. Firmex and Divestopedia surveyed over 480 investment bankers and M&A advisors worldwide to ... Dentons share their insights on the key findings in the report. , Highlights ...
Breaking Biology News(10 mins):
(Date:11/6/2018)... ... November 06, 2018 , ... ... for clinical trial data collection and management. TrialKit ™, an eClinical platform, ... generation devices can quickly and easily sign in to the app via facial ...
(Date:11/5/2018)... ... November 05, 2018 , ... USARAD ... by Siemens Healthineers and several healthcare VC firms announces at Distributed Health 2018 ... a history by purchasing tokens and obtaining its first radiology interpretations, one of ...
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades ... Transcription Activator Like (TAL) effector code technology for applications in advancing research in ... technology in plants. Since its discovery in 2009, the efficacy of TAL effector-based DNA ...
(Date:11/3/2018)... ... ... Triangle Insights Group, a premier life sciences consulting firm, announced today that ... the United States, appearing on this year’s Inc. 5000 list. Since its inception ... over the previous three years. , Separately, Triangle Insights was also ranked on ...
Breaking Biology Technology:
Cached News: